Karyopharm Therapeutics is an innovation-driven pharmaceutical company that is dedicated to improving the lives of patients with cancer and other major diseases. With a focus on discovery, development, and commercialization of medicines, Karyopharm aims to deliver effective treatments to those in need. Their primary area of focus is nuclear export in cancer, and they have developed a cutting-edge technology known as Selective Inhibitor of Nuclear Export (SINE).

This technology targets the fundamental mechanism of oncogenesis, where healthy cells transform into cancerous cells. With four unique drug candidates in clinical development, Karyopharm is working on developing treatments for both hematologic and solid tumors. The company is committed to putting patients at the forefront and is actively conducting ongoing clinical trials for their lead drug candidate and next-generation programs.

Join Karyopharm in their mission to revolutionize cancer treatment and improve patient outcomes